# The Novo Nordisk study POSEIDON - including 18,904 patients across 18 countries - showed that cardiovascular (CV) inflammation remains highly prevalent among people with cardiovascular disease.

*biotech · news · 2026-05-26 · The Manila Times*

## Key points

- The POSEIDON study found 42% of ASCVD patients with CKD or heart failure have CV inflammation.
- CV inflammation, measured by hsCRP ≥2 mg/L, persists despite standard cholesterol, blood pressure, and sugar treatments.
- POSEIDON enrolled 18,904 patients across 18 countries from 2023 to 2025, making it one of the largest studies of its kind.
- Recent global guidelines now recommend using elevated hsCRP to guide intensive cardiovascular preventive strategies.

**Companies:** Novo Nordisk
**Countries:** Denmark, Greece

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/26/tmt-newswire/globenewswire/novo-nordisk-global-observational-study-reveals-2-in-5-people-with-cardiovascular-disease-have-cardiovascular-inflammation-increasing-their-risk-of-heart-attack-and-stroke/2351446)

---

Canonical: https://newsio.io/n/113419ba-cc1e-4a49-8ee2-68bec2ecc26e/the-novo-nordisk-study-poseidon-including-18904-patients-across-18-countries-sho
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works